| Name |
Class |
Indications |
Forms Available |
Onset/Duration |
Typical Dose |
Actions |
Side effects/Toxicity |
|
Albuterol(Proventil, Ventolin, Volmax)
albuterol medical facts
 |
Selective
β2-agonist |
Asthma/Bronchospasm, COPD |
MDI (90
µg/actuation) DPI (200
µg/actuation)
Nebulized (0.083%, 0.5%)
PO (2-,4-,8-mg tablets, 2-mg/5mL syrup) |
5 minutes (inhaled), 30 minutes
(oral)/4 to 6 hours |
Outpatient MDI use: 2 puffs q4h prn
Outpatient nebulizer use: 2.5 mg in 2 mL saline q4h prn
Intubated patients: 4 to 8 puffs q1-4 h
Emergency Treatment: 2 to 4 puffs q15 min, or
continuous nebulized
Oral maintenance: 4 mg PO tid |
|
Tachycardia, palpitations, hypokalemia,
lactic acidosis |
|
Aminophylline(Phyllocontin, Truphylline)
Methylxanthines for chronic obstructive pulmonary
disease (COPD)
 |
Methylxanthine |
Asthma or other obstructive lung disease
exacerbation, respiratory muscle weakness |
PO (100-, 200-mg tablets; 225-mg sustained release,
105 mg/5mL elixir) Rectal (250,500 mg; 300-mg/5mL
liquid)
IV |
Minutes (IV)/approx.6 hours |
Emergency treatment: Load 6 mg/kg, then 0.5 -1.2
mg/kg/h infusion IV Maintenance adult: 400 mg PO
daily, divided tid-qid
Maintenance child: 16 mg/kg daily, divided tid-qid |
|
Tachycardia and palpitations, nausea, agitation and
seizures |
|
Amphotericin B (Liposomal preparations Amphotec and
AmBisome)
amphotericin B medical facts
 |
Antifungal antibiotic |
Prevention and treatment of invasive pulmonary
aspergillosis in immunocompromised patients |
Nebulized IV |
N/A |
0.1 mg/kg/d, or 3 mL of 10-mg/mL solution or 10 mg
by nebulizer bid |
|
Bronchospasm; potential for nephrotoxicity and
ototoxicity |
|
|
|
arformoterol tartrate (Brovana)
Brovana
Official FDA information, side effects and uses.
 |
Long acting selective
β2-adrenergic
bronchodilator |
Chronic obstructive pulmonary disease (COPD),
including chronic bronchitis and emphysema |
Nebulized 2 mL of arformoterol tartrate
solution packaged in 2.1 mL unit-dose |
|
15 mcg administered twice a day (morning
and evening) by nebulization |
|
|
| Atropine
Complete Atropine information
 |
Anticholinergic |
Reduction of excessive secretions, especially before
procedures such as bronchoscopy and intubation |
Oral (0.4, 0.6 mg) IV, IM |
5 minutes/1 to 2 hours |
0.4 to 0.6 mg PO/IV/IM q2h prn |
|
Dry mouth, blurred vision, mydriasis, urinary
retention, confusion |
|
Beclomethasone Diproprionate )Beclovent, Vanceril,
Beconase, Vancenase)
Complete Beclomethasone Dipropionate information
 |
Inhaled corticosteroid |
Asthma and COPD maintenance therapy, rhinitis,
sinusitis |
MDI (42
µg/ actuation) Nasal (42
µg/actuation) |
Duration: ~8 hours |
2 to 3 puffs tid-qid (age > 12) 1 to 2 puffs
tid-qid (children ages 6 to 12 |
|
Hoarseness, thrush, sore throat, possible growth
retardation |
| Beractant (Survanta)
Complete Beractant Information
 |
Surfactant replacement |
Treatment of neonatal respiratory distress syndrome
(RDS), prophylaxis of RDS in neonates weighing less than
1250 g |
Intratracheal liquid instillation (25 mg
phospholipid/mL) |
Minutes/12 hours |
4 mL/kg; repeat doses q6h prn |
Reduces surface tension |
Mucous plugging, transient decrease in PaO2 and
hemodynamic instability |
|
|
| Name |
Class |
Indications |
Forms Available |
Onset/Duration |
Typical Dose |
Actions |
Side effects/Toxicity |
| Budesonide (Pulmicort, Rhinocort)
Complete Budesonide Info
 |
Inhaled corticosteroid |
Asthma and COPD maintenance
therapy, rhinitis, sinusitis |
DPI (200
µg/actuation) Nasal (32
µg/actuation) |
Duration:~12 hours |
1 to 4 puffs bid |
|
Hoarseness, thrush, sore throat, possible growth
retardation |
|
Budesonide/Formoterol (Symbicort)
Complete Budesonide/Formoterol Fumarate Dihydrate
information
 |
Long acting selective
β2-agonist
with inhaled corticosteroid |
Asthma, COPD |
Budesonide 80
µg
and formoterol 4.5
µg/actuation
Budesonide 160 µg
and formoterol 4.5
µg/actuation
|
15 minutes/~12 hours |
2 puffs bid |
|
|
|
Colfosceril Palmitate, Cetyl Alcohol, Tyloxapol (Exosurf)
 |
Surfactant replacement |
Treatment of neonatal
respiratory distress syndrome (RDS), prophylaxis of RDS
in neonates weighing less than 1350 g |
Intratracheal liquid
instillation (13.5 mg/mL when reconstituted) |
Minutes/12 hours |
5 mL/kg q12h, three doses |
Reduces surface tension |
Pulmonary hemorrhage, mucous plugging, transient
decrease in PaO2 |
| Colistimethate (Colistin, Coly-Mycin)
Complete Colistin info
 |
Polypeptide antibiotic |
Gram-negative pneumonia, especially Pseudomonas
species |
Nebulized (75 mg/mL) IV |
N/A |
150 mg by nebulizer bid |
Binds phospholipids, dirupting bacterial cell
membranes |
Nephrotoxicity, neurotoxicity including
neuromuscular blockade |
|
Cromolyn Sodium (Intal, Nasalcrom)
Cromolyn Aerosol Solution facts and comparsions
 |
Cromone |
Asthma, allergic rhinitis,
conjunctivitis, mastocytosis |
MDI (800
µg/actuation) DPI
(20 mg/actuation)
Nebulized (20 mg/2 mL)
Nasal (5.2 mg/actuation)
Oral (100 mg)
Ophthalmic
|
10 minutes/2 to 6 hours |
MDI: 2 puffs qid DPI: 20 mg qid
Nebulized: 20 mg qid |
Mast cell stabilization |
Bronchospasm, arthralgia, angioedema, eosinophilic
pneumonia, pulmonary infiltrates, mucosal irritation |
|
Dexamethasone (Decadron, Dexacort)
Dexamethasone Official FDA information, side effects and
uses.
 |
Systemic (or inhaled) corticosteroid |
Multiple |
MDI (dexamethasone sodium phosphate, 100
µg/actuation)
Nasal (dexamethasone sodium
phosphate, 100 µg/actuation)
PO
(0.25-,0.5-,0.75-,1-,1.5-,2-,4-,6-mg tablets; 0.5 mg/mL
elixir and solution; 0.5-mg/0.5-mL solution)
IV, Topical, ophthalmic |
Duration: more than 48 hours |
Systemic: varies Inhaled maintenance therapy: 3
puffs tid-qid |
|
Multiple |
|
| Name |
Class |
Indications |
Forms Available |
Onset/Duration |
Typical Dose |
Actions |
Side effects/Toxicity |
| Dornase Alfa (DNAase, Pulmozyme)
Complete Dornase Alfa (Recombinant Human
Deoxyribonuclease; DNase) information
 |
Enzyme/secretion thinner |
CF and other conditions with thick purulent
secretions |
Nebulized (1 mg/mL) |
15 minutes/2 hours |
2.5 mg qd-bid |
Digests DNA in purulent secretions |
Tachycardia and palpitations, nausea, agitation, and
seizures |
| Ephedrine
Complete Ephedrine information
 |
Nonselective adrenergic agonist |
Asthma/bronchospasm |
Nasal (0.25% spray, 0.5% drops, 1% jelly) PO (25,
50 mg)
SC/IM/IV (25, 50 mg/mL) |
15 minutes/4 hours |
Maintenance bronchodilator: 25 to 50 mg PO q4h prn
Severe bronchospasm: 12.5 to 25 mg SC, IM, or IV |
|
Tachycardia, palpitations, cardiac ischemia,
hypertension, tremor |
| Flunisolide (AeroBid, Nasalide)
Complete Flunisolide information
 |
Low-potency inhaled corticosteroid |
Asthma and COPD maintenance therapy, rhinitis,
sinusitis |
MDI (250
µg/actuation) Nasal (25
µg/actuation) |
Duration:~12 hours |
2 to 4 puffs bid |
|
Hoarseness, thrush, sore throat, possible growth
retardation |
| Fluticasone (Flovent, Flonase)
fluticasone inhalation medical facts
 |
High-potency inhaled corticosteroid |
Asthma and COPD maintenance
therapy, rhinitis, sinusitis |
MDI (44, 110,220
µg/actuation)
DPI (50, 110, 250
µg/actuation)
Nasal (50 µg/actuation)
Topical
|
Duration: ~12 hours |
MDI: 220-880 ug (1 to 4 puffs) bid DPI: 100-500 ug
(1 to 2 doses) bid
Nasal: 1 spray per nostril bid |
|
Hoarseness, thrush, sore
throat, possible growth retardation |
|
Fluticasone/Salmeterol (Advair)
Advair Diskus medical facts
 |
Long acting selective
β2-agonist
with inhaled corticosteroid |
Asthma, COPD |
Advair Diskus 100/50, Advair
Diskus 250/50, and Advair
Diskus 500/50 |
Duration: ~12 hours |
1 puff bid |
|
|
|
Formoterol (Foradil)
Foradil Aerolizer (formoterol) medical facts
 |
Long acting selective
β2-agonist |
Asthma, COPD |
Aerolizer (12µg
capsule) |
~12 hours |
Aerolizer: 1 capsule bid |
|
Tachycardia, palpitations (less
than short-acting agents), paradoxic bronchospasm |
|
Glycopyrrolate (Robinul)
Robinul
(glycopyrrolate) medical facts
 |
Anticholinergic |
Reduction of excessive
secretions, especially before procedures such as
bronchoscopy and intubation |
Oral (1, 2 mg) IV, IM |
5 minutes/1 to 2 hours |
Oral: 1 to 2 mg q4-6h IV/IM: 0.1 to 0.2 mg prn |
Reduces secretion of the liquid component of mucous |
Dry mouth, blurred vision, urinary retention,
confusion |
| Heparin
heparin
medical facts
 |
Anticoagulant |
Prophylaxis and treatment of deep venous thrombosis
and pulmonary embolism |
IV, SC |
Minutes/~2 hours |
DVT prophylaxis: 5000 units SC q12h |
Activates antithrombin III |
Excessive bleeding and bruising, contraindicated in
active hemorrhage, recent intracranial hemorrhage,
active pericarditis |
|
Hydrocortisone (A-HydroCort, Cortef, Hydrocortone,
Solu-Cortef, Cortisol)
hydrocortisone medical facts
|
Systemic corticosteroid |
Multiple |
PO (5, 10, 20 mg; 10-mg/5-mL suspension) Rectal
(10% foam = 90 mg/application; 100 mg/60mL)
IV |
Duration:~8 hours |
Adrenal insufficiency: 100 mg IV q6h Asthma/COPD
exacerbation: 100 to 200 mg PO/IV q6h
Pediatric: 1 mg/kg PO bid |
|
Multiple |
| Ibuprofen (Advil, Motrin, Nuprin, Rufen)
ibuprofen medical facts
 |
Nonsteroidal antiinflammatory drug (NSAID) |
Diverse inflammatory processes; pain; fever |
Oral (200-,800-mg tablet) Rectal
(120-,200-,300-,600-mg suppository) |
Duration:~6 hours |
Antiinflammatory/analgesic: 600 PO q4-6h |
|
Peptic ulcer, increased bleeding, bronchospasm,
nephropathy, nausea |
|
Indomethacin (Indameth, Indocin)
indomethacin medical facts
 |
Nonsteroidal antiinflammatory drug (NSAID) |
Diverse inflammatory processes; pain; fever |
Oral (25-, 50-mg tablet, 25 mg/5 mL suspension)
Rectal (50 mg suppository)
IV |
Duration:~6 hours |
Antiinflammatory/analgesic: 50 PO q6h |
|
Peptic ulcer, increased bleeding, bronchospasm,
nephropathy, nausea |
| Infrasurf |
Surfactant replacement |
Treatment of neonatal
respiratory distress syndrome (RDS), prophylaxis of RDS
in neonates weighing less than 1250 g |
Intratracheal liquid installation |
Minutes/12 hours |
3 mL/kg q12h |
Reduces surface tension |
Mucous plugging, transient decrease in PaO2 and
hemodynamic instability |
|
|
| Name |
Class |
Indications |
Forms Available |
Onset/Duration |
Typical Dose |
Actions |
Side effects/Toxicity |
|
Ipratropium (Atrovent)
ipratropium inhalation medical facts
 |
Anticholinergic bronchodilator |
COPD, asthma, and other obstructive lung diseases;
rhinorrhea |
MDI (18
µg/actuation)
Nebulized (0.02%)
Nasal Spray (0.03%, 0.06%) |
1 minute/6 hours |
MDI: 2 puffs q6h prn Nebulized: 2.5 mL (0.5 mg)
q6h prn
Nasal: 2 sprays per nostril q6h prn |
|
Palpitations, dry mouth, blurred vision, acute
exacerbation of narrow-angle glaucoma, urinary retention |
|
Isoproterenol (Isuprel)
isoproterenol inhalation medical facts
 |
β-Adrenergic
agonist |
Asthma/bronchospasm |
MDI (80, 120, 131
µg/actuation)
Nebulized (0.25%, 0.5%, 1%)
Sublingual (10, 15 mg)
IV (200
µg/mL) |
2 minutes/2 hours |
MDI: 1 to 2 puffs q4h prn Nebulized: 2 mL of 0.25%
solution in 2-mL saline q4h prn
Sublingual: 10 to 20 mg PO qd
IV: 0.01 to 0.02 mg IV q2h prn |
|
Tachycardia, palpitations, tremor, hypo- or
hypertension, flushing |
|
Ketorolac (Toradol)
Toradol
(ketorolac) medical facts
 |
Nonsteroidal antiinflammatory drug (NSAID) |
Diverse inflammatory processes; pain; fever |
Oral (10-mg tablet) IV, IM |
30 minutes/6 hours |
Antiinflammatory/analgesic: 60
mg IM May repeat q6h x 1 |
|
Peptic ulcer, increased bleeding, bronchospasm,
nephropathy, nausea |
|
Levalbuterol (Xopenex)
levalbuterol medical facts
 |
Selective
β2-agonist |
Asthma/bronchospasm, COPD, especially in patients
bothered by side effects of racemic albuterol |
Nebulized (0.625- and 1.25-mg unit doses) |
5 minutes/6 hours |
0.625 to 1.25 mg q4h prn |
|
Tachycardia, palpitations, tremor |
|
Lidocaine
lidocaine and prilocaine topical medical facts
 |
Topical anesthetic |
Cough, before bronchoscopy |
Nebulized Intratracheal instillation |
10 seconds/30 minutes |
Nebulized: 2 mL of 4% solution Intratracheal
instillation: 2 mL of 1% solution |
Local anesthesia |
Cardiac arrhythmia, decreased level of
consciousness, increased risk of aspiration |
|
Metaproterenol (Alupent, Metaprel)
metaproterenol medical facts
 |
β-adrenergic
agonist (some
β2-selectivity |
Asthma/bronchospasm, COPD |
MDI (650
µg/actuation)
Nebulized (0.4%, 0.6%, 5%)
PO (10-, 20-mg tablets, 10-mg/5mL syrup) |
5 to 30 minutes/4 hours |
MDI: 2 to 3 puffs q3-4 h prn Nebulized: 2.5 mL of
0.6% solution q6h prn
Oral, adult: 20 mg q6h prn
Oral, children >27 kg: 10 mL q6h prn
Oral, children <27 kg: 5 mL q6h
prn |
|
Tachycardia, palpitations, cardiac ischemia, tremor |
|
Methylprednisolone (Medrol, Solu-Medrol)
methylprednisolone medical facts
 |
Systemic corticosteroid |
Multiple |
PO (2-, 4-,8-,16-,24-,32-mg) IV (injection and
slowly absorbed suspension) |
Duration: 12 to 24 hours |
Asthma or COPD exacerbation: 125 mg IV, then 60 mg
q6h Pediatric: 1 to 2 mg/kg/day IV q6h
Systemic: varies |
|
Multiple |
|
Montelukast (Singulair)
montelukast medical facts
 |
Leukotriene synthesis inhibitor |
Asthma, allergic rhinitis |
PO (5-mg chewable, 10-mg tablet) |
3 hours/24 hours |
10 mg qd (adults) 5 mg qd (children) |
|
Churg-Strauss syndrome? |
|
N-acetylcysteine (Mucomyst, Mucosil, NAC)
acetylcysteine medical facts
 |
Secretion thinner |
Cystic fibrosis and other conditions with thick
secretions, acetaminophen overdose |
Nebulized or oral solution (10%, 20%) |
5 minutes/1 to 2 hours |
3 to 10 mL of 20 % solution tid-qid |
Cleaves disulfide bonds in mucous |
Bronchospasm (usually administered with a
bronchodilator), rhinitis, nausea, mild elevation in
liver enzymes with oral administration |
|
Nedocromil (Tilade)
nedocromil inhalation medical facts
 |
Cromone |
Asthma, allergic rhinitis |
MDI (1.75 mg/actuation) |
30 minutes/6 to 12 hours |
2 puffs qid, then reduce to bid as tolerated |
Mast cell stabilization |
Bronchospasm, eosinophilic pneumonia |
|
Omalizumab
(Xolair)
Xolair (omalizumab)
medical facts
 |
IgE Blocker |
moderate-to-severe persistent asthma who
have a positive skin test or
in vitro reactivity
to a perennial aeroallergen |
SC |
2 to 4 weeks |
150 to 375 mg is administered SC every 2
or 4 weeks. |
inhibits the binding of IgE to the
high-affinity IgE receptor (FcåRI) on the surface of
mast cells and basophils. |
Anaphylaxis, presenting as bronchospasm,
hypotension, syncope, urticaria, and/or angioedema of
the throat or tongue, |
|
Pentamidine (NebuPent)
pentamidine medical facts
 |
Antibiotic |
Prophylaxis against (nebulized) or treatment of (IV)
PCP in sulfa-allergic patients |
Nebulized IV |
N/A |
PCP prophylaxis: 300 mg in 5 mL saline, nebulized
monthly PCP treatment: 4 mg/kg IV qd |
Unknown |
Cough, bronchospasm |
|
Pirbuterol (Maxair)
pirbuterol inhalation medical facts
 |
Selective
β2-agonist |
Bronchospasm/asthma, COPD |
MDI (200
µg/actuation) |
5 minutes/5 hours |
1 to 2 puffs q4h prn |
|
Tachycardia, palpitations, tremor |
|
Prednisolone (Delta-Cortef, Hydeltrasol, Prelone,
Pedipred, Predicort)
prednisolone medical facts
 |
Systemic corticosteroid |
Multiple |
PO (5-mg tablet; 15-mg/5mL, 5-mg/5-mL liquid)
Ophthalmic |
12 to 24 hours |
Varies |
|
Multiple |
|
Prednisone (Deltasone, Meticorten, Orasone, Sterapred)
prednisone medical facts
 |
Systemic corticosteroid |
Multiple |
PO (1, 2.5, 5, 10, 20, 25, 50 mg; 5-mg/1mL solution)
IV |
12 to 24 hours |
Varies |
|
Multiple |
|
Racemic Epinephrine (Adrenalin, AsthmaHaler,
AsthmaNefrin, Bronkaid, Epinal, Primatene Mist,
Vaponephrine)
Complete Epinephrine information |
Nonselective adrenergic agonist |
Anaphylaxis; asthma/bronchospasm; upper airway edema
and laryngospasm |
MDI (160, 200, 250
µg/actuation)
Nebulized (1%, 1.25%, 2.25% solution)
SC (1:1000)
IV (1:10,000 and 1:100,000) |
1 minute/1 hour |
MDI: 1 puff q4h prn Nebulized: 0.5 mL of 2.25%
solution in 2 mL saline, q6h prn
Anaphylaxis: 0.4 mg SC |
Bronchodilation; blocks histamine release by mast
cells; vasoconstriction |
Tachycardia, palpitations, cardiac ischemia,
hypertension, tremor |
|
Ribavirin (Virazole)
ribavirin medical facts
 |
Antiviral |
RSV and severe influenza infection |
Nebulized |
60 minutes/7 hours (children) to 24 hours (adults) |
6 g in 300 mL saline, continuous nebulization 18/24
hr for 3 to 7 days |
Unknown |
Bronchospasm, pulmonary edema, hypoxia, hypotension,
cardiac arrhythmia (drug contraindicated in pregnancy;
should be used with extreme caution with mechanical
ventilators. |
|
Salmeterol (Serevent)
salmeterol medical facts
 |
Long acting selective
β2-agonist |
Maintenance therapy of asthma, COPD and other
obstructive diseases; especially useful in preventing
overnight exacerbation |
MDI (25
µg/actuation)
DPI (50
µg/actuation) |
10 minutes/12 hours |
MDI: 2 to 4 puffs bid DPI: 1 inhalation bid |
|
Tachycardia, palpitations (less than short-acting
agents), paradoxic bronchospasm |
|
Terbutaline (Brethine, Bricanyl, Brethaire)
terbutaline medical facts
 |
Selective
β2-agonist |
Asthma/bronchospasm |
MDI (200
µg/actuation)
PO (2.5, 5 mg)
IV (1 mg/mL) |
5 to 30 minutes/4 hours |
Emergency nebulized treatment: 1 mg in 2 mL saline
q4h prn Emergency parenteral treatment: 0.25 to 0.5 mg
SC or IV q4h prn
Inhaled maintenance therapy: 2 puffs q4-6h prn
Oral maintenance therapy: 5 to 15 mg PO tid |
|
Tachycardia, palpitations, tremor, paradoxic
bronchospasm |
|
Tiotropium Bromide (Spiriva)
tiotropium inhalation medical facts
 |
Long-acting anticholinergic |
Maintenance treatment of bronchospasm associated
with chronic obstructive pulmonary disease (COPD),
including chronic bronchitis, emphysema, or both |
Handihaler (18µg
capsules) |
24 hours |
Once daily |
|
Dry mouth, constipation, increased
heart rate, blurred vision, glaucoma, urinary
difficulty, and urinary retention.
Contraindicated in patients with a history of
hypersensitivity to atropine or its derivatives,
including ipratropium, or to any component of this
product.
|
|
Theophylline
theophylline medical facts
 |
Methylxanthine |
Asthma, especially for nocturnal symptoms and in
children; COPD and respiratory muscle weakness |
PO (100-,200-mg capsules; 100-, 125-, 200-, 250-,
300-mg tablet; 50-, 60-, 65-, 75-, 100-, 125-, 130-,
200-, 250-, 260-, 300-, 400-, 450-, 500-,mg extended
release; 50-mg/5-mL, 80-mg/15-mL elixir; 50-mg/5mL, 80-,
150-mg/15 mL syrup) IV |
30 minutes/ varies widely |
Maintenance therapy: 13 to 24 mg/kg/day, divided
q6-8h Emergency treatment: Load 4.7 mg/kg, then 0.24
to 0.55 mg/kg/h infusion IV |
|
Tachycardia and palpitations, nausea, agitation and
seizures |
|
Thrombin |
Coagulant |
Hemorrhage |
Topical |
seconds/hours |
1 mL reconstituted |
Converts fibrinogen to fibrin clot |
Large clot formation may cause airway obstruction |
|
Tobramycin (TOBI)
Tobramycin Official FDA information, side effects and
uses.
 |
Aminoglycoside antibiotic |
Patients with cystic fibrosis, and possibly other
forms of bronchiectasis, colonized with Pseudomonas
species |
Nebulized (300 mg/5 mL unit dose) IV
Ophthalmic |
Hours/Weeks |
300 mg bid x 28 days, then off x 28 days |
Interferes with bacterial protein translation;
reduces pulmonary levels of Pseudomonas species
and other gram-negative bacteria |
Ototoxicity, nephrotoxicity |
|
Triamcinolone Acetonide (Azmacort)
Azmacort medical facts
 |
Inhaled corticosteroid |
Asthma and COPD maintenance (and rarely,
exacerbation) therapy; rhinitis, sinusitis |
MDI (100
µg/actuation)
Nasal (55
µg/actuation)
Oral (1-, 2-, 4-, 8-mg tablets; 2-mg/mL, 4-mg/mL
suspension)
IV |
~8 hours |
MDI: 2 to 4 puffs tid-qid, tapered to bid as
tolerated Pediatric MDI: 1 to 2 puffs tid-qid, tapered
to bid as tolerated
Systemic: varies |
|
Hoarseness, thrush, sore
throat, possible growth retardation |
|
Warfarin (Coumadin)
Coumadin (warfarin) medical facts
 |
Anticoagulant |
Prophylaxis and treatment of deep venous thrombosis
and pulmonary embolism |
PO |
2 to 3 days/approx. 1 week |
2 to 8 mg PO qd |
Inhibits production of vitamin K-dependent factors
V, VII, IX, X |
Excessive bleeding and bruising; contraindicated in
active hemorrhage, recent intracranial hemorrhage,
active pericarditis |
|
Zafirlukast (Accolate)
zafirlukast medical facts
 |
Leukotriene receptor antagonist |
Asthma, allergic rhinitis |
PO (20-mg tablet) |
3 hours/12 hours |
20 mg PO bid |
|
Churg-Strauss syndrome? |
|
Zileuton (Zyflo)
zileuton medical facts
 |
5-Lipoxygenase inhibitor |
Asthma, allergic rhinitis |
PO (600 mg) |
1.5 hours/6 hours |
600 mg PO qid |
|
Hepatotoxicity |